您要查找的是不是：
- median surviving dose 半數存活劑量
- The median survival for the 10 patients was 19 months. 這10例患者的中位生存時(shí)間為19個(gè)月。
- The median survival time for the entire sample was 34 months. 二年及五年的存活率各為65%25及25%25。
- The median survival was 11 months, with a 3-year survival of 24%. 平均生存時(shí)間是11個(gè)月，3年生存率為24%25。
- HR, 0.68), with a prolongation of median survival by 6 weeks. 整體危險比為0.;68），且延長(cháng)整體存活率時(shí)間達6周。
- Median survival in the patients with SCLC was 3months, with NSCLC was 8. 5 months. SCLC和NSCLC的中位生存期分別為3個(gè)月和8.;5個(gè)月。
- The median survival was 18.5 months with a 1, 2 and 3-year actuarial survivalrate of 50%, 29% and 25%, respectively. 經(jīng)隨訪(fǎng);平均生存時(shí)間已達18.;5個(gè)月; 1、2和3年的生存率分別達到50%25、29%25和25%25。
- Median survival time(MST)was 10 months. Median time to progression (MTTP) was 8 months. 中位生存時(shí)間(MST)為10個(gè)月,中位進(jìn)展時(shí)間(MTTP)為8個(gè)月。
- The median survival of the CMFVP group with four or more positive nodes was 9.1 years... 應譯為：科學(xué)家正在研制和試驗由分泌細胞因子的基因工程腫瘤細胞組成的癌疫苗。
- The median survival time was 60 months for the patients after EMR,no difference in survival between operatinon group and EMR group( P =0.729 39). EMR治療患者中位生存期 6 0個(gè)月 ;手術(shù)與EMR治療生存時(shí)間無(wú)顯著(zhù)性差異 (P =0 .;72 939)。
- The median survival time(MST) of N-Control, C-Control and Dex was 10, 17 and 16 days respectively, and had no difference each other(P0.05). 三、(l)各組大鼠術(shù)后存活時(shí)間:N一Control組(n=7) MST二10天、C一Control組(n=8)MST=17天和Dex組(n=8)MST=16天，術(shù)后存活時(shí)間無(wú)明顯差別;
- Results The median survival time was 53.5 months.Conclusion The prognosis is in turns related to the clinical period,patho... 結果6例的中位生存期為53.;5個(gè)月;均無(wú)瘤生存。
- A dose of this stuff will purge you! 這種藥只須一劑就能讓你通便！
- The overall 1-,2-, 3-, 5- year survival rates for AMM treated by radical surgery were 55.26%, 37.76%, 31.21% and 20.34% respectively, the median survival time was 21.24 months. 根治性手術(shù)治療AMM的1、2、3、5年生存率分別為55.;26%25、37
- The overall 1-,2-,3-,5-,10-year survival rates for AMM were 47.25%,34.17%,27.28%,17.78% and 8.89% respectively,the median survival time was 16.78 months. AMM的1年、2年、3年、5年和10年生存率分別為47.;25%25、34
- thirty-seven per cent survival dose 百分之三十七存活劑量
- Results: (1) The median survival time(MST) of N-Control, C-Control and Dex was 9, 18 and 15 days respectively, and had no difference each other(P>0.05). 結果：(1)各組大鼠術(shù)后存活時(shí)間：N-Control組(n=7)MST=9天、C-Control組(n=8)MST=18天和Dex組(n=8)MST=15天，術(shù)后存活時(shí)間無(wú)明顯差別；
- The response rate in patients with ECOG PS of 0-1 was significiantly higher than that with ECOG PS of 2. Median survival period was 11 mo and 1 year-survival rate reached 50%. ECOG PS評分0-1分病人有效率明顯高于ECOG PS評分2分病人。 中位生存期為11 mo,1年生存率為50%25。
- Give him the dose of his own medicine. [諺]以其人之道還治其人之身。
- The response rate were 37.0%(10/27)for VM26regimen and 38.7%(12/3 1)for IFO regimen,median survival time was 8.3 months for VM26regimen and 8.1 months for IFO regimen. 威猛聯(lián)合方案組有效率為37.;0%25（10/27），中位生存期為8
